Fig. 1 · Structure

Documents & Downloads

PHT-427

Cat. No. A11032 CAS 1191951-57-1

AKT Inhibitor

PHT-427 is a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Akt Ki 2.7 μM
PDK-1 Ki 5.2 μM

Cellular Effect

Cell Line Activity Value Description Reference
BXPC-3 IC50 57 μM Cytotoxicity against human BxPC3 cells by MTT assay [PMID: 21353784]
BXPC-3 IC50 6.3 μM Inhibition of Akt phosphorylation in human BxPC3 cells by Western blotting [PMID: 19734051]

In Vitro Studies

In BxPC3 cells, single treatment with PHT-427 produced a Caspase-3 activity effect that was not significantly higher than zero. In a competition assay using CGA-modified MM-captured AKT protein, AKT bands in the SC79 and PHT-427 groups were clearly detected by Western blot compared with the DTT group. Following treatment with serial dilutions of PHT-427, no significant difference was seen in normalised MCF10A-WT and CDH1−/− cell counts. In AsPC1 cells, PHT-427, MK-2206, or their combination showed no significant effect on Caspase-3 activity. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Caspase activity in BxPC3 cells

Cell-based study · BxPC3 cells [1]

In BxPC3 cells, single treatment with PHT-427 produced no statistically significant effect on Caspase-3 activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Caspase-3 activityReported result either single treatment showed an effect that was not significantly higher than zero (p-value 0.21 and 1 for PHT-427 and MK-2206, respectively, one-tailed t-test)[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM
Exposure duration
16 h at 37 °C in a 5% CO2 atmosphere
Method
cells + Caspase-3 substrate + compound X + media
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: PHT-427

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Combinatorial drug-response screening (S30); Results > Cell line-specific drug combinations and validation (S60); Methods > Microfluidic setup (S111); Methods > Preparation of cells for microfluidic experiments (S140, S142); Methods > Preparation of drugs and Caspase-3 substrate (S147, S148, S152); Methods > Data processing (S165); Fig. 3 legend (S200)

Caspase-3 activity: Caspase-3 activity; comparator: cells + Caspase-3 substrate + media + media — Results > Cell line-specific drug combinations and validation (S60); Fig. 3 legend (S200)

AKT detection following probe competition

Cell-based study · CGA-modified MM-captured AKT protein [2]

PHT-427 was added to compete with the CGA-modified MM probe in captured AKT protein. Compared with the DTT group, AKT bands were clearly detected by Western blot in the SC79 and PHT-427 groups.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
AKT concentration was determined using SDS-PAGE and Western blotReported result compared with the DTT group, the bands of AKT in the SC79 and PHT-427 groups were clearly detected by Western blot[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM
Method
added to compete with the CGA-modified MM probe
Reported limits
Not stated in the sentences used: schedule, vehicle.
Methods and source locations

Compound reported in the paper: PHT-427

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.8. Competitive Test against AKT Using CGA-Modified MMs (S58, S60, S64, S65, S66); 3. Results > 3.3. CGA Binds to the PH Domain of AKT (S116)

AKT concentration was determined using SDS-PAGE and Western blot: AKT concentration was determined using SDS-PAGE and Western blot; comparator: captured AKT proteins were released with 250 μL of DTT (100 μM) — 2. Materials and Methods > 2.8. Competitive Test against AKT Using CGA-Modified MMs (S66); 3. Results > 3.3. CGA Binds to the PH Domain of AKT (S116)

Normalised cell counts following treatment

Cell-based study · MCF10A-WT and CDH1−/− [3]

Normalised MCF10A-WT and CDH1−/− cell counts 48 h after treatment with serial dilutions of PHT-427: No significant difference was seen.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Normalised MCF10A-WT and CDH1−/− cell countsReported result Normalised MCF10A-WT and CDH1−/− cell counts 48 h after treatment with serial dilutions of PHT-427: No significant difference was seen.[3]

Literature-Reported Treatment Conditions

Exposure duration
48 h
Method
treatment with serial dilutions
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: PHT-427

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.1. Allosteric AKT Inhibitors Preferentially Target Breast Cells Lacking CDH1 (S9); 4. Materials and Methods > 4.3. Nuclei Enumeration Assay (S99); Figure 1 legend (S153, S156)

Normalised MCF10A-WT and CDH1−/− cell counts: Normalised MCF10A-WT and CDH1−/− cell counts; comparator: MCF10A-WT and CDH1−/−; normalised to the vehicle control for each cell line. — 2. Results > 2.1. Allosteric AKT Inhibitors Preferentially Target Breast Cells Lacking CDH1 (S9); Figure 1 legend (S153)

Caspase activity in AsPC1 cells

Cell-based study · AsPC1 cells [1]

In AsPC1 cells, treatment with PHT-427, MK-2206, or their combination showed no significant effect on Caspase-3 activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Caspase-3 activityReported result no significant effect was shown for AsPC1 cells for PHT-427, MK-2206, or their combination (p-value = 1, 0.68 and 0.28, respectively, one-tailed t-test)[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM
Exposure duration
16 h at 37 °C in a 5% CO2 atmosphere
Method
cells + Caspase-3 substrate + compound X + media
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: PHT-427

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Combinatorial drug-response screening (S30); Results > Cell line-specific drug combinations and validation (S61); Methods > Microfluidic setup (S111); Methods > Preparation of cells for microfluidic experiments (S140, S142); Methods > Preparation of drugs and Caspase-3 substrate (S147, S148, S152); Methods > Data processing (S165); Fig. 3 legend (S200, S203, S204); Fig. 4 legend (S206)

Caspase-3 activity: Caspase-3 activity; comparator: control condition (cells + Caspase-3 substrate + media + media); one-tailed t-test: z-score equal to 0 (i.e., median activation across all conditions). — Results > Cell line-specific drug combinations and validation (S61); Fig. 3 legend (S200, S204)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1191951-57-1
Applications AKT Inhibitor
Formula C20H31N3O2S2
Molecular Weight 409.6
SMILES
CCCCCCCCCCCCC1=CC=C(C=C1)S(=O)(=O)NC2=NN=CS2

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 75 mg/mL (183.1 mM)
Water Insoluble
Ethanol 55 mg/mL (134.27 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
5% DMSO+95% Corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Eduati F, Utharala R, Madhavan D, et al. A microfluidics platform for combinatorial drug screening on cancer biopsies. Nat Commun (2018). PMID: 29934552 DOI: 10.1038/s41467-018-04919-w Source material
  2. [2] Gao J, He X, Ma Y, et al. Chlorogenic Acid Targeting of the AKT PH Domain Activates AKT/GSK3β/FOXO1 Signaling and Improves Glucose Metabolism. Nutrients (2018). PMID: 30249058 DOI: 10.3390/nu10101366 Source material
  3. [3] Bougen-Zhukov N, Nouri Y, Godwin T, et al. Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells. Cancers (Basel) (2019). PMID: 31540244 DOI: 10.3390/cancers11091359 Source material

Added to your cart

View Cart Checkout
Loading...